As the production and distribution of SARS-CoV-2 vaccines ramps up in the United States, there is a need to ensure that communities at highest risk for severe COVID-19 morbidity and mortality are targeted. As of February 2021, the Pfizer/BioNTech and Moderna mRNA vaccines, which were approved by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization (EUA) in late 2020, remai...
Annual Reports
HCCI’s Health Care Cost and Utilization Reports
Yearly reviews of spending, price and utilization trends for commercially-insured Americans. Learn more about our methodology, definitions, and other resources.